Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa

• Published in: Gastroenterology (New York, N.Y. 1943) Vol. 113; no. 5; p. 1660
• Main Authors: Lau, D T, Everhart, J, Kleiner, D E, Park, Y, Vergalla, J, Schmid, P, Hoofnagle, J H
• Format: Journal Article
• Language: English
• Published: United States 01.11.1997
• Subjects: Adult; Aged; Aspartate Aminotransferases - blood; Chronic Disease; DNA, Viral - blood; Female; Follow-Up Studies; Hepatitis B - complications; Hepatitis B - mortality; Hepatitis B - therapy; Hepatitis B Surface Antigens - blood; Humans; Interferon alpha-2; Interferon-alpha - therapeutic use; Male; Middle Aged; Recombinant Proteins; Survival Rate
• ISSN: 0016-5085
• DOI: 10.1053/gast.1997.v113.pm9352870

Therapy with interferon alfa (IFN-alpha) leads to remission of disease in one third of patients with chronic hepatitis B. The aim of this study was to better define the long-term prognosis of this outcome. One hundred three patients with chronic hepatitis B who underwent IFN-alpha therapy in three clinical trials between 1984 and 1991 were followed up for serological status, biochemical evidence of liver disease, and liver complications or mortality through 1994. Among 103 patients, 31 (30%) responded to therapy with loss of hepatitis B e antigen and viral DNA from serum. Responders were more likely than nonresponders to be women, black, and to have more severe liver disease including cirrhosis (P < 0.05). Up to 11 years (mean, 6.2 years) after therapy, a higher percentage of responders than nonresponders were still negative for hepatitis B e antigen (94% vs. 40%; P < 0.001) and hepatitis B surface antigen (71% vs 8.3%; P < 0.001). Overall, the rate of liver-related complications and death did not differ by IFN-alpha response, but with adjustment for cirrhosis, nonresponders had higher rates of liver-related complications and mortality (hazard ratio, 13.7; 95% confidence interval, 3.0-63.5). The response to IFN-alpha therapy in chronic hepatitis B is usually a sustained improvement in disease markers and, when cirrhosis is considered, patient outcome.